Page 17 - உலகளாவிய பெருநிறுவன தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Evotec AG: Evotec Launches BeLAB2122 , Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Wolters Kluwer ELM Solutions to Explore Major Changes in Attorney-Client Relationships in Upcoming Webinar
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Evotec AG: Evotec And Exscientia Announce Start of Human Clinical Trials of Novel Immuno-Oncology Drug
EXSCIENTIA TO LEAD CLINICAL DEVELOPMENT PHASE
EVOTEC RETAINS CO-OWNERSHIP RIGHTS DURING CLINICAL DEVELOPMENT
HAMBURG, GERMANY / ACCESSWIRE / April 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia s next generation 3-D evolutionary AI-design platform, Centaur Chemist
(R). The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-me
DGAP-News: Evotec SE / Key word(s): Miscellaneous
09.04.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
SELECTIVE, NOVEL A2A RECEPTOR ANTAGONIST IS MOST ADVANCED ASSET ARISING FROM JOINT VENTURE BETWEEN EVOTEC AND EXSCIENTIA
EXSCIENTIA TO LEAD CLINICAL DEVELOPMENT PHASE
EVOTEC RETAINS CO-OWNERSHIP RIGHTS DURING CLINICAL DEVELOPMENT
Hamburg, Germany, 09 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia s next generation 3-D evolutionary AI-design platform, Centaur Chemist
Press release content from Business Wire. The AP news staff was not involved in its creation.
Wolters Kluwer Podcast Sheds Light on Key Factors Impacting Effective Banking Compliance
April 9, 2021 GMT
MINNEAPOLIS (BUSINESS WIRE) Apr 9, 2021
Timothy R. Burniston, Senior Advisor, Regulatory Strategy with Wolters Kluwer Compliance Solutions, shares insights for U.S. financial institutions adapting to current and expected regulatory priorities and oversight measures in a new podcast.
ADVERTISEMENT
In this 37-minute podcast, “Consumer Compliance: Shift Priorities to Follow Changes in Regulatory Oversight Trends,” Burniston looks at ways banks may seek to fortify their compliance measures to prepare for the residual impact of the pandemic on consumers. He also examines the regulatory ramifications of leadership changes in Washington, and the anticipated increase in regulatory change. He notes that more than 40 percent of financial institutions are accelerating their “investmen
vimarsana © 2020. All Rights Reserved.